Over the last 13 years, Fangning has served leading Pharma, biotech and MedTech companies on business strategy, innovation, medical affairs, organization transformation etc.

Fangning is a regular speaker at leading China healthcare conferences, e.g., Biocentury China Healthcare Summit (2018), China Trials (2015-19), China Healthcare Investment Conference (2016, 2018), publishes articles focusing on China healthcare innovation and spearheaded efforts to establish China Drug Innovation Index (CDII) since 2015

Prior to McKinsey, Fangning has worked as research scientist at Pfizer Global R&D center (Groton, CT), conducting drug discovery research as medicinal chemist. Fangning obtained her MBA degree from Northwestern University. She is a Board member of Bayhelix.

Greg founded ChinaBio® Group in 2007 to help life science companies and investors achieve success in China. ChinaBio® works with US, European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. ChinaBio® has also organized over 30 conferences in China focused on investment and partnering, including the ChinaBio® Partnering Forum which draws nearly 1000 attendees from around the world to China each spring. Greg is also co-founder of two investment groups that have funded over 50 biotechnology and medical device companies in the US and China, and Executive Editor of ChinaBio® Today: a widely read newsletter covering the China life science industry. He also serves on the board of a medical device and cancer drug company, and formerly the BayHelix Group, a group of (mostly) Chinese life science executives. Headquartered in Shanghai, ChinaBio® has staff in San Diego, Palo Alto, and Basel, Switzerland. Greg lives and works in Shanghai and visits California a few times a year to enjoy the blue skies and sandy beaches.

Yingjie is currently Head of Roche Pharma Partnering China, based in Shanghai. She oversees all BD activities in China from scouting to alliance for opportunities across all therapeutic areas where Roche has an interest.

Before joining Roche, Yingjie worked as BD Associate Director at GSK R&D Shanghai site, focusing on scientific collaboration transaction and alliance. Yingjie started her industrial BD career at AZ Innovation Center China as Discovery Alliance Manager. She was a technology transfer professional at Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

Yingjie is a trained molecular biologist from Max-Planck Institute of Biochemistry in Munich, Germany, and a graduate from Uppsala University, Sweden.

Dr. Wei (William) CAO is the Founder, Chairman and CEO of Gracell Biotechnologies Group. Together with an industry veteran team, Dr. Cao has created Gracell to capture special opportunity of cell therapy for global market. Through external partnership and in-house R&D effort, Gracell has been rapidly progressing with novel CAR-T programs to address the industry’s key issues.
He is a seasoned front runner with over three decades of experience in biotech and R&D. Before conception of Gracell today, he was the co-founder and CEO of Cellular Biomedicine Group (Nasdaq: CBMG); served as senior scientific management positions at Chiron (Novartis and Bayer) and Affymetrix (ThermoFisher). William also has over 80 issued patents and applications for advanced cell therapies.
Dr. Cao earned a Bachelor’s degree in Medicine from Fudan University / Shanghai Medical College, China and a PhD degree in Pharmacology from Medical College of Virginia, USA. He has extensive research experience in immune-pharmacology field at Harvard Medical School and Stanford University Medical Center. He is the director of International Chinese Stem Cell Foundation (ICSCF). Dr. Cao received prestigious White Magnolia Award from Shanghai City.